APIXABAN FOR THE REDUCTION OF THROMBO-EMBOLISM IN PATIENTS WITH DEVICE-DETECTED SUB-CLINICAL ATRIAL FIBRILLATION
Newsletter June 2020
ARTESiA Protocol and Background & Rationale
ARTESiA Protocol Overview ARTESiA Background and Rationale
Upcoming Events
There are no upcoming events at this time.
Paced P-wave duration as a significant predictor for atrial high-rate episodes in patients with cardiac implantable electronic devices https://t.co/oAeAptlYCl
By ARTESiA Investigator @adribaran and colleagues
By ARTESiA Investigator @adribaran and colleagues
"How should I treat patients with subclinical atrial fibrillation and atrial high-rate episodes? Current evidence and clinical importance"
https://t.co/95Y6GCDV2u
https://t.co/95Y6GCDV2u
A systematic review and meta-analysis in
(JOURNAL SITE) suggests that any device detected atrial high rate episode confers a meaningful stroke risk
https://t.co/J4nJZBsbpQ
(JOURNAL SITE) suggests that any device detected atrial high rate episode confers a meaningful stroke risk
https://t.co/J4nJZBsbpQ
